Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macupatide and Eloralintide in Type 2 Diabetes and Obesity/Overweight
NCT07215559Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of macupatide, eloralintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Oct 2025; status: active, not recruiting.
02
Drugs
macupatideeloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07215559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215559.